A malignant eccrine poroma responds to isotretinoin (13-cis-retinoic acid).
In treating a patient with a malignant eccrine poroma, in-vitro studies suggested resistance to dactinomycin and doxorubicin. A trial of weekly 5-fluorouracil produced no response. Likewise, a cycle of cisplatinum and cytarabine was associated with continued progression of the disease. Use of 13-cis retinoic acid induced a partial remission that lasted for 8 weeks with minimal toxicity. The mechanism of action is not known, but local tumor necrosis with sparing of the adjacent normal tissue suggests high specificity.
D006607:Adenoma, Sweat Gland / Q000188:drug therapy* / Q000601:surgery; D000970:Antineoplastic Agents / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D006801:Humans; D015474:Isotretinoin; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009378:Neoplasms, Multiple Primary; D013544:Sweat Gland Neoplasms / Q000188:drug therapy* / Q000601:surgery; D013848:Thigh; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014212:Tretinoin; D015474:Isotretinoin